EN002 / Enkang Pharma - LARVOL DELTA

Safety and preliminary efficacy of a first-in-class DRIP inhibitor EN002 topical gel in non-melanoma skin cancer and actinic keratosis: An international phase I study (SID 2025) - "The phase 1 study provided preliminary clinical evidence of a favorable benefit-risk profile of a novel topical therapy for patients with naïve, recurrent or relapsed NMSC or AK, who represent unmet medical needs. In the ongoing Phase II study with expanded treatment duration, the first 4 enrolled patients all achieved 100% clearance in 9 weeks."

Clinical • Late-breaking abstract • P1 data • Actinic Keratosis • Basal Cell Carcinoma • Bowens Disease • Dermatology • Genetic Disorders • Non-melanoma Skin Cancer • Skin Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Skin Cancer